HC Wainwright Initiates Monte Rosa Therapeutics With Buy, $25 Target
HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics' stock with a Buy rating and a $25 price target, implying a 109.6% upside from the previous close.
HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics' stock with a Buy rating and a $25 price target, implying a 109.6% upside from the previous close.